Loading clinical trials...
Loading clinical trials...
Phase I/II Study of Safety and Efficacy of Tofacitinib Combined With Chidamide in Patients With Relapsed and Refractory Extranodal Natural Killer/T Cell Lymphoma
Conditions
Interventions
tofacitinib
chidamide
Locations
1
China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Start Date
January 1, 2019
Primary Completion Date
December 31, 2019
Completion Date
December 31, 2021
Last Updated
July 26, 2018
NCT06406556
NCT01787409
NCT03493451
NCT04509466
NCT02168140
NCT01769222
Lead Sponsor
Sichuan University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions